Dementia and Alzheimer Disease

Over a 6-month treatment period, changes in apathy for methylphenidate-treated patients were not associated with performance on the remaining cognitive tests.

The chief medical officer at Eisai provided context towards the ongoing initiatives to further the efficacy and safety profile of lecanemab, an FDA-approved treatment for early Alzheimer disease. [WATCH TIME: 3 minutes]

The trial will use phase 2a to determine the optimal dosage while phase 2b will assess efficacy and long-term safety of the optimized dose against a placebo arm.

The drug showed a strong safety profile and met primary endpoints, showing efficacy in slowing clinical and biological decline and supporting further investigation in a phase 2/3 trial.

Marketed as Zunveyl for mild-to-moderate Alzheimer disease, ALPHA-1062 is considered a new-generation acetylcholinesterase inhibitor with expected minimal gastrointestinal adverse events.

A duo of experts talked about the association of long-term exposure to fine particulate matter from wildfires and the increased risk of dementia among older adults. [WATCH TIME: 7 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The vaccine induced a specific humoral immune response, positively affecting several AD-related biomarkers, and showed potential as a treatment for AD, with further trials planned.

The director of the Brain Health Observatory at the University of Southern California talked about integrating blood tests into primary care to better triage patients with Alzheimer disease, reduce unnecessary referrals, and shorten appointment wait times. [WATCH TIME: 7 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on congenital muscular dystrophy.

Lantheus's acquisition of NAV-4694 aims to enhance early Alzheimer’s disease detection and complement their PET imaging tools, potentially improving diagnosis, staging, and treatment monitoring.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 26, 2024.

The president and CEO at Alzheon shared recent insights into neurodegenerative diseases that suggest a single toxic trigger may be responsible for conditions like Alzheimer disease, leading to potential early intervention and treatment strategies. [WATCH TIME: 10 minutes]

The president and CEO at Alzheon talked about a novel Alzheimer disease drug that shows promising early results in reducing key biomarkers and stabilizing cognitive function in a challenging patient population. [WATCH TIME: 10 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on progressive multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 19, 2024.

The investigational therapy, which targets neurodegeneration, has shown promise in phase 2 and 3 studies of Alzheimer disease and Parkinson disease, with additional studies on the way.

The neuroradiologist at Mayo Clinic discussed the categorization of biomarkers for Alzheimer disease, focusing on core biomarkers specific to the disease and those reflecting related pathologies. [WATCH TIME: 8 minutes]

A duo of experts from Mayo Clinic discussed how recent developments in clinical criteria for diagnosing limbic-predominant amnestic neurodegenerative syndrome allow for more accurate differentiation from Alzheimer disease. [WATCH TIME: 9 minutes]

Lomecel-B is made from living cells called medicinal signaling cells that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45.

The neuroradiologist at Mayo Clinic talked about revised guidelines for diagnosing and staging Alzheimer disease, which reflect recent scientific advancements and integrate cutting-edge biomarkers and diagnostic tools. [WATCH TIME: 6 minutes]

In new analyses of a pivotal phase 3 study, eplontersen resulted in beneficial effects on neuropathy impairment and quality of life in patients regardless of sex or change in body mass index.

Take a look at some of the most-anticipated clinical trials with expected data readouts in the second half of 2024 that researchers and clinicians in neurology should keep an eye out on.

The director of the Weill Cornell Women’s Brain Initiative discussed emerging research that highlight the significant impact of sex hormones on women's brain health, and how it influences conditions like Alzheimer disease. [WATCH TIME: 8 minutes]